1. Management Challenges in CLL

3. This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

4. Program Overview

5. Initial Case Presentation (2005)

6. Initial Case Presentation: Tumor Markers

7. Using Prognostic Markers in the Clinic

8. Using Biomarkers in Selecting Chemoimmunotherapy

9. Using Biomarkers in Selecting Novel Therapies

10. Using NGS to Detect Subclonal Mutations

11. Case Continued: Treatment With Chemotherapy

12. Case Continued: Treatment With Novel Agents

13. Bleeding-Related Events With Ibrutinib

14. Case Continued: Fluctuating Lymphocyte Count

15. Case Continued: Disease Progression

16. Case Continued: Bone Marrow Biopsy

17. Clinical Considerations in Assessing Disease Progression on Ibrutinib

18. Clinical Considerations When Switching to Venetoclax: Minimizing Risk for TLS

19. iwCLL Guidelines: Considerations for Revised Approach to Response/Disease Progression

20. Resistance to Ibrutinib: Mutations

21. Case Continued: Initiating Treatment With Venetoclax

22. Minimizing Risk for TLS

23. Goals of Therapy

24. Achieving MRD Negativity With Venetoclax

25. Response to Venetoclax Post Ibrutinib

26. CAR T-Cell Therapy Post Ibrutinib

27. Potential Treatment Options After a BCR Signaling Inhibitor

28. Conclusions

29. Abbreviations

30. Abbreviations (cont)

31. Abbreviations (cont)